KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Current Taxes (2021 - 2024)

Moderna (MRNA) has disclosed Current Taxes for 4 consecutive years, with $4.0 million as the latest value for Q3 2024.

  • For Q3 2024, Current Taxes fell 92.86% year-over-year to $4.0 million; the TTM value through Sep 2024 reached $4.0 million, down 92.86%, while the annual FY2023 figure was $63.0 million, 31.25% up from the prior year.
  • Current Taxes hit $4.0 million in Q3 2024 for Moderna, down from $7.0 million in the prior quarter.
  • Across five years, Current Taxes topped out at $1.6 billion in Q1 2022 and bottomed at $4.0 million in Q3 2024.
  • Average Current Taxes over 4 years is $291.6 million, with a median of $63.0 million recorded in 2023.
  • On a YoY basis, Current Taxes climbed as much as 31.25% in 2023 and fell as far as 95.85% in 2023.
  • Moderna's Current Taxes stood at $876.0 million in 2021, then crashed by 94.52% to $48.0 million in 2022, then soared by 31.25% to $63.0 million in 2023, then plummeted by 93.65% to $4.0 million in 2024.
  • According to Business Quant data, Current Taxes over the past three periods came in at $4.0 million, $7.0 million, and $52.0 million for Q3 2024, Q2 2024, and Q1 2024 respectively.